Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer

IntroductionTriple-negative breast cancer (TNBC) is negative for hormone receptors and human epidermal growth factor receptor 2 (HER2). In stage I TNBC, adjuvant therapy or follow-up are performed according to risk factors, but clinical trial data is scarce. In recent years, it has been reported tha...

Full description

Bibliographic Details
Main Authors: Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Rui Kitadai, Asuka Kawachi, Shu Yazaki, Momoko Tokura, Motoko Arakaki, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Aiko Maejima, Yuki Kojima, Tadaaki Nishikawa, Kazuki Sudo, Tatsunori Shimoi, Emi Noguchi, Yasuhiro Fujiwara, Hirokazu Sugino, Sho Shiino, Akihiko Suto, Masayuki Yoshida, Kan Yonemori
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
stage I triple-negative breast cancer
HER2-low
HER2-0
prognosis
prognostic factor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1157789/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1157789/full

Similar Items